CATIE
2005
Clinical Antipsychotic Trials of Intervention Effectiveness
In 1,493 patients with chronic schizophrenia, olanzapine, quetiapine, risperidone or ziprasidone achieved the same time to discontinuation as perphenazine, with most patients stopping treatment by 18 months.
Result
Primary endpoint: Time to all-cause discontinuation
~74% discontinued within 18 months across arms; olanzapine had the longest time-to-discontinuation but most weight gain.
- Subtopic
- Pharmacology context
- Design
- Multi-phase pragmatic RCT, USA
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- NICE CG178 Psychosis
- Source
- Lieberman JA, et al. N Engl J Med. 2005;353(12):1209-1223.doi 10.1056/NEJMoa051688
Discussion & critique
Backdrop for why psychosocial augmentation matters: even with modern antipsychotics, real-world adherence is poor.